Join to View Full Profile
619 19th St SBirmingham, AL 35249
Phone+1 205-934-4011
Dr. Bal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2019
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2015 - 2018
Kettering Health Network/Kettering Medical CenterResidency, Internal Medicine, 2012 - 2015
Bharti Vidyapeeth Medical CollegeClass of 2012
Certifications & Licensure
AL State Medical License 2019 - 2025
OH State Medical License 2012 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Clinical Trials
- Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) Start of enrollment: 2021 Sep 22
Publications & Presentations
PubMed
- Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and M...Ajai Chari, Susan Bal, Sikander Ailawadhi, Amrita Krishnan, Krina K Patel
Clinical Lymphoma, Myeloma & Leukemia. 2025-03-11 - 2 citationsInternational myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal
Leukemia. 2025-03-01 - Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.Luciano J Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R Dholaria, Kelly N Godby
Blood Cancer Journal. 2025-02-05
Journal Articles
- Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma—ReplySusan Bal, MD, JAMA Oncology
- Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-Risk Cytogenetic FactorsSusan Bal, Benjamin Djulbegovic, Saad Z Usmani, JAMA Oncology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
